Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 11/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338624 | 1.00 | RIPK1 (0.40) | RIPK1HTR1ACTSSKDM4ERECQL | |
| SCHEMBL25821042 | 1.00 | RIPK1 (0.40) | RIPK1HTR1ACTSSKDM4ERECQL | |
| SCHEMBL30547507 | 0.87 | RIPK1 (0.40) | RIPK1CTSS | |
| SCHEMBL30338752 | 0.87 | ALDH1A1 (0.39) | RIPK1KDM4E | |
| SCHEMBL25816886 | 0.87 | ALDH1A1 (0.39) | RIPK1KDM4E | |
| SCHEMBL25256324 | 0.86 | RIPK1 (0.40) | RIPK1KDM4EDGAT2 | |
| SCHEMBL30339402 | 0.86 | RIPK1 (0.40) | RIPK1KDM4EDGAT2 | |
| SCHEMBL25294541 | 0.85 | RIPK1 (0.46) | RIPK1HTR1AKDM4ERECQLTP53 | |
| SCHEMBL30338797 | 0.85 | RIPK1 (0.46) | RIPK1HTR1AKDM4ERECQLTP53 | |
| SCHEMBL25817044 | 0.85 | RIPK1 (0.42) | RIPK1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885HTR1A 2931/4885CTSS 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.